nimesulide has been researched along with Kidney Failure, Chronic in 6 studies
nimesulide: structure
nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
Excerpt | Relevance | Reference |
---|---|---|
"The occurrence of chronic renal failure in strict relationship with maternal nimesulide assumption in this case is strongly suggestive for a pharmacological damage, either direct or mediated by renin angiotensin inhibition, and possibly modulated by genetic factors, likely to account for the different outcome of similarly treated patients." | 1.31 | [Neonatal chronic kidney failure associated with cyclo-oxygenase-2 inhibitors administered during pregnancy]. ( Amore, A; Conti, G; Coppo, R; Gianoglio, B; Peruzzi, L; Porcellini, G, 2001) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 5 (83.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Jikki, PN | 1 |
Magnani, C | 1 |
Moretti, S | 1 |
Ammenti, A | 1 |
Peruzzi, L | 2 |
Gianoglio, B | 2 |
Porcellini, MG | 1 |
Coppo, R | 2 |
Krämer, BK | 1 |
Balasubramaniam, J | 1 |
Porcellini, G | 1 |
Conti, G | 1 |
Amore, A | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 189 |
Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 1078 |
Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 78 |
Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 303 |
Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 134 |
Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 141 |
Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 42 |
Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 352 |
Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 264 |
Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 668 |
Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 1506 |
Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 214 |
Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 26 |
Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 54 |
Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 9 |
Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 23 |
Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 290 |
Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 8 |
Placebo Arm | 21 |
6 other studies available for nimesulide and Kidney Failure, Chronic
Article | Year |
---|---|
Apparently unexplainable hypoglycemia in a diabetic patient--clue for renal failure?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Diabetic Nephropathies; Glomer | 2008 |
Neonatal chronic renal failure associated with maternal ingestion of Nimesulide as analgesic.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Female; Humans; Infant; I | 2004 |
Neonatal end-stage renal failure associated with maternal ingestion of cyclo-oxygenase-type-1 selective inhibitor nimesulide as tocolytic.
Topics: Adult; Cyclooxygenase Inhibitors; Female; Humans; Infant, Newborn; Kidney Failure, Chronic; Obstetri | 1999 |
Renal effects of cyclo-oxygenase-type-2 inhibition.
Topics: Cyclooxygenase Inhibitors; Female; Humans; Infant, Newborn; Kidney Failure, Chronic; Pregnancy; Sulf | 2000 |
Selective COX-2 inhibitors and nephrotoxicity.
Topics: Acute Kidney Injury; Animals; Cyclooxygenase Inhibitors; Female; Fetal Diseases; Humans; Kidney Fail | 2000 |
[Neonatal chronic kidney failure associated with cyclo-oxygenase-2 inhibitors administered during pregnancy].
Topics: Adult; Cyclooxygenase Inhibitors; Female; Humans; Infant, Newborn; Kidney Failure, Chronic; Pregnanc | 2001 |